A Blood Test Revolution in Women’s Health – PromarkerEndo’s Clinical Leap Forward on Endometriosis.
- Noel Ong
- Jun 6
- 5 min read
Updated: Jun 23
Announcement
Let’s be honest: endometriosis has long been one of the most underdiagnosed and misunderstood medical conditions in women's health. A silent disruptor, it causes pain, fertility issues, and decades-long suffering, often without a name. Until now, the only path to a diagnosis was invasive laparoscopic surgery, usually after seven years of misdiagnosis. That’s not a system built for healing. But what if we could change that narrative with a simple blood test?
Proteomics International Laboratories Ltd (ASX: PIQ) may have just done that.
The announcement on 26 May 2025, unveiling PromarkerEndo at the World Congress on Endometriosis in Sydney, appears to be more than just data—it’s the kind of breakthrough that could shift the clinical standard. The company’s proprietary non-invasive blood test has not only proven itself in real-world clinical validation but is now poised for commercial rollout. If you've been watching the precision diagnostics space, now is the time to pay close attention to PIQ.
PromarkerEndo – From Concept to Clinical Application
Presented to leading experts at the World Congress, the latest results from a 704-participant study have validated PromarkerEndo’s capability across all stages of endometriosis, using a single, universal test. This isn't just a lab theory—it’s a working diagnostic tool.
The test delivers a straightforward ‘traffic light’ risk score—low, moderate, or high—making it accessible and immediately useful for both general practitioners and specialists. Sensitivity and specificity metrics were consistently impressive across disease stages
Table 1: The integrated PromarkerEndo test demonstrated excellent discrimination in diagnosing all stages of disease when compared against symptomatic controls and general population controls, and improved upon the performance of the previously published results (source: PIQ)
These numbers are compelling when compared to existing diagnostics like the PSA test for prostate cancer, which only achieves an AUC of 0.68. PromarkerEndo is not just competitive—it’s superior.
Targeting a $9.7 Billion Problem in Australia Alone
Endometriosis affects 1 in 9 women and girls globally, with economic costs estimated at $9.7 billion annually in Australia. In the realm of fertility care, its undiagnosed presence skews outcomes and complicates treatments. With 70–80% of early cases going unnoticed due to the limitations of current tools, PromarkerEndo has the potential to fill a long-vacant diagnostic void.
Commercial Rollout – What Comes Next?
According to Proteomics’ timeline, PromarkerEndo is on track for commercial launch in Australia in Q3 CY25, with global markets to follow. The test will be delivered using the same Direct-to-Consumer (DTC) digital framework already in place for PromarkerD, which is now being used across Australia and in the US.
Key steps ahead include:
Finalising ISO 15189 accreditation
Building clinician and primary care engagement
Partnering with fertility clinics and women's health providers
Preparing regulatory submissions and licensing discussions
This isn’t just a lab breakthrough—it’s a market-ready innovation.
A Word from the Scientist Behind It All
Proteomics International Managing Director Dr Richard Lipscombe commented:
“this is a major step forward in making non-invasive endometriosis diagnosis a reality. PromarkerEndo has the potential to dramatically reduce diagnostic delays with its simplicity, accuracy, and broad applicability - including in fertility care. The advances support our commercialisation strategy and reinforce the potential for PromarkerEndo to become a standard part of the clinical diagnostic pathway.”
Industry Backing and Independent Validation
Backing the science is a robust network of research institutions, including the Royal Women’s Hospital and the University of Melbourne, and strong validation from international experts like Professor Peter Rogers. Their message is clear: this isn’t just innovation—it’s transformation.
Concluding Comments – Samso’s View
In a market saturated with speculative diagnostics and unfulfilled promises, Proteomics International look to be charting a different path—grounded in hard science, clinical validation, and strategic delivery. To the scientists reading this, it is what precision medicine was always meant to be.
According to the company, PromarkerEndo doesn’t just diagnose a disease; it dismantles a barrier. It brings immediacy, accuracy, and dignity to patients who’ve waited far too long. And for investors, this may be indicating that this is a company that not only understands unmet medical needs but has the tech and team to solve them.
With PromarkerD already in market, PromarkerEso next in line, and now PromarkerEndo advancing with serious commercial intent, PIQ is shaping up as a quiet achiever in precision diagnostics.
Looks like Q3 will be an interesting time.
Reasons Why Samso Helps Your Research.
Here at Samso, we pride ourselves on delivering content for investors that is independent and informed by over three decades of experience in the industry. Our content is well-researched and is only created if I see merit in discussing the company's story.
Investors can view our three main products in Coffee with Samso, Samso News and Samso Insights.
There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals.
Most importantly, investors need to be diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew is my parting comment. As they say, Rome was not built in a day, and the Great Wall is a great phenomenon because it took centuries to build.
As usual, Happy Investing and remember, always DYOR.
References:
ASX: PIQ, 26 May 2025 – PromarkerEndo advances toward clinical use
[Diagnostics Journal, March 2025 Cover – PromarkerD Results]
[Quarterly Activities Report, 24 April 2025, ASX: PIQ]
To support our independent nature of our work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiate for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018.
Disclaimer
The information or opinions provided herein do not constitute investment advice, an offer or solicitation to subscribe for, purchase or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints.
Share to Grow: Your Bonus
Samso has just released an eBook: How to Add Value to your Share Portfolio
A lesson on geological models sought by mining companies that gives insight and an understanding of which portfolios are better - and potentially more lucrative – investments. Click here to download this eBook.
If you find this article informative and useful, please help me share the information. I try and write about topics that are interesting and have the potential to be of investment value. It is not easy to find stories that fit those parameters. If you or your organisation see the benefit of what Samso is trying to achieve and have a need to share your journey, please contact me at noel.ong@samso.com.au.
Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insights from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research.
Comments